Third Arc Bio Emerges with $165 Million to Innovate in Solid Tumors and Autoimmune Diseases A team of Johnson & Johnson veterans launched Third Arc Bio with $165 million in [….]
While still in the early stages of development, Baltimore’s MyMD Pharmaceuticals lead therapeutic compound MYMD-1 appears to have the potential to be a pipeline in a pill that can play a role in multiple autoimmune and fibrotic diseases where inflammation plays a key role.
Launched in New York, two-year-old data science company DrugViu, which has created a comprehensive and diverse Real-World Evidence Platform for immunological research, will relocate its headquarters to Northern Virginia.
Blacksburg biotech company Landos Biopharma Inc. has gone public. An initial public offering of stock, priced at $16 a share, was expected to raise $100 million to develop possible new [….]
